FDA issues partial hold affecting Gilead’s Magrolimab, an investigational monoclonal antibody by Editor | Jan 26, 2022 | Government, Regulatory & Policy News, Hospitals, LATEST NEWS, WORLD NEWS | 0 USA – The FDA has temporarily halted trials of Gilead Sciences’ anti-CD47 antibody... Read More